INTRODUCTION AND OBJECTIVES: Clinically node-positive (cNþ) bladder cancer is considered Stage IV disease and the mainstay of treatment is chemotherapy. However, a subset of patients undergoes consolidative radical cystectomy (RC). We examined the clinical outcomes of patients with cNþ bladder cancer treated with chemotherapy and RC and developed a risk prediction model to facilitate risk-stratification and management. METHODS: We identified adult patients with cTany cN1-3 cM0 urothelial carcinoma of the bladder treated with systemic chemotherapy followed by RC from 2004-2014 in the NCDB. The associations of clinicopathologic features with overall survival (OS) were evaluated using Cox regression, and a simplified risk score was developed.
INTRODUCTION AND OBJECTIVES: Clinically node-positive (cNþ) bladder cancer is considered Stage IV disease and the mainstay of treatment is chemotherapy. However, a subset of patients undergoes consolidative radical cystectomy (RC). We examined the clinical outcomes of patients with cNþ bladder cancer treated with chemotherapy and RC and developed a risk prediction model to facilitate risk-stratification and management. METHODS: We identified adult patients with cTany cN1-3 cM0 urothelial carcinoma of the bladder treated with systemic chemotherapy followed by RC from 2004-2014 in the NCDB. The associations of clinicopathologic features with overall survival (OS) were evaluated using Cox regression, and a simplified risk score was developed.
RESULTS: A total of 491 patients received chemotherapy followed by RC. Median age was 62 years, and the median number of lymph nodes removed was 15 (IQR 8, 24) . At RC, 10% of patients were ypT0, and 35% were ypN0. Over a median follow-up of 18.7 (IQR 8, 39) months, 160 patients died of any cause. 1-, 5-, and 8-year OS were 69%, 34%, and 29%, respectively. On multivariable analysis, pT stage (HR 2.48; p[0.002; HR 1.92; p[0. 01 for pT4 and pT3 vs <pT2, respectively), and pN stage (HR 5.19; p<0.001, HR 2.70; p<0.001, and HR 1.87; p[0.01 for pN3, pN2 , and pN1 vs pN0, respectively) were independently associated with worse OS. A simplified risk score was developed (Figure) . Five-year predicted OS for risk scores of 0-1, 2-3, and >3 ranged from 11% to 65% (Figure) .
CONCLUSIONS: Survival for patients with cNþ bladder cancer treated with chemotherapy and RC is highly variable, ranging from 11% to 65% at 5 years depending on clinicopathologic features. A simplified risk score can facilitate post-operative risk-stratification and selection of patients for adjuvant therapies.
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MP26-13 COMPARATIVE EFFECTIVENESS OF CHEMORADIATION VERSUS CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR CLINICALLY NODE-POSITIVE (CND) BLADDER CANCER
Osama Alalao*, Catrina Mueller-Leonhard, Providence, RI; Simon P. Kim, Aurora, CO; Ali Amin, Christopher Tucci, Gyan Pareek, Anthony Mega, Dragan Golijanin, Boris Gershman, Providence, RI INTRODUCTION AND OBJECTIVES: There are limited data regarding the optimal management of clinically node-positive (cNþ) bladder cancer. Although the mainstay of treatment is chemotherapy, it is unclear whether local therapy in the form of radiation versus surgery provides superior oncologic outcomes. We, therefore, examined the comparative effectiveness of chemoradiation versus chemotherapy and radical cystectomy for the management of cNþ bladder cancer.
METHODS: We identified adult patients aged 18-69 with Charlson index 0-1 with cTany cN1-3 cM0 urothelial carcinoma of the bladder treated with systemic chemotherapy followed by !40 cGy radiation therapy (chemoþRT) or systemic chemotherapy followed by radical cystectomy (chemoþRC) from 2004-2014 in the NCDB. The associations of clinicopathologic features with overall survival (OS) were evaluated using Cox regression.
RESULTS: A total of 421 patients were included in the study, of whom 335 underwent chemoþRC and 86 underwent chemoþRT. Compared to patients who underwent chemoþRC, patients who underwent chemoþRT were older (median 62 vs 58 years, p[0.006), had more advanced cN stage (15% vs 6% cN3, 48% vs 44% cN2, and 37% vs 50% cN1, p[0.01), and were less likely to be treated at an academic/research program (41% vs 59%, p<0.001), although there were no statistically significant differences in cT stage. Of patients who underwent RC, 34% were ypN0 and 10% were ypT0. During a median follow-up of 24.2 (IQR 14.0, 44.0) months, 213 patients died of any cause. In univariable analyses, chemoþRC was associated with improved OS compared to chemoþRT (HR 0.63; p[0.003; Figure) . However, on multivariable analysis, chemoþRC was not associated with statistically significantly improved survival (HR 0.87; p[0.44) .
CONCLUSIONS: In this observational study, there was no statistically significant difference in OS between chemoradiation or chemotherapy and RC among patients with cNþ bladder cancer after multivariable adjustment.
INTRODUCTION AND OBJECTIVES:
There remains a perception that cystectomy following prior pelvic irradiation (PPI) confers worse outcomes. With the increasing experience in robot assisted cystectomy (RAC), we report the feasibility and peri-operative outcomes of patients undergoing post-pelvic irradiation robot-assisted cystectomy (P-PIRAC) compared to RAC in patients without PPI.
METHODS: We performed a prospective single-centre review of 529 patients treated with cystectomy from January 2009 to June 2018. 316 patients underwent RAC, of which 25 (7.9%) received PPI (Group A). This was compared with to 291 patients who did not receive PPI (Group B). Co-morbidities were quantified using the Charlson co-morbidity index (CCI), and peri-operative complications were recorded in each group. RESULTS: Patients in Group A were older (mean age 72 vs 68 years, p [ 0.028) but fitter (ASA Score 3: 4% vs 16%, p[0.012). Whilst there was no statistically significant difference in baseline demographics (gender, race, body mass index), a greater number of patients in Group A received chemotherapy (44% vs 15%, p < 0.001).
There was no differences in short and median term perioperative outcomes between the two groups (Table 1) , and on multivariate analysis, only increasing age (OR 1.04, 95% CI 1.01 -1.07, p [ 0.017) and longer operative time (OR 1.005, 95% CI 1.001 -1.009, p [ 0.012) were associated a higher 90-day complication rate. PPI was not associated with an increased intra-operative (OR 0.62, 95% CI 0.13 -2.86, p [ 0.539) or 90-day complication rate (OR 0.82, p [ 0.740) (Table 2) .
CONCLUSIONS: P-PIRAC should be standard of care in high volume RAC units. It provides durable short and medium term outcomes and is a safe option with complication rates not dissimilar to RAC in patients without PPI. T2 to non-organ confined pathologic stage !T3 or Nþ at radical cystectomy (RC) is common and can significantly increase the risk of cancerspecific mortality (CSM). We assessed the ability of a genomic subtyping classifier (GSC) to predict pathological upstaging in a multi-institutional cohort of patients with clinical T1-T2 bladder cancer treated with RC.
METHODS: A cohort of 206 patients with clinical high-grade, organ-confined (cT1-T2, N0M0) treated with RC and bilateral PLND without neoadjuvant chemotherapy (NAC) was selected from the registries of 7 academic hospitals. Precystectomy bladder tumor transurethral resection FFPE specimens were submitted for
